AFP and hepatocellular carcinoma: Currently, the American Association for the Study of Liver Diseases (AASLD) recommends offering screening for HCC with an ultrasound or contrast-enhanced CT or MRI and a serum α-fetoprotein (AFP) every 6 months when HCC risk is at least 1.5% per year, which includes persons with established cirrhosis and chronic hepatitis B virus infection [3].